These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24616318)

  • 1. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
    Chun SG; Iyengar P; Gerber DE; Hogan RN; Timmerman RD
    J Clin Oncol; 2015 Feb; 33(5):e25-6. PubMed ID: 24616318
    [No Abstract]   [Full Text] [Related]  

  • 2. [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
    Toffart AC; Sakhri L; Moro-Sibilot D
    Rev Pneumol Clin; 2013 Apr; 69(2):111-6. PubMed ID: 23561899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
    Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
    J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
    [No Abstract]   [Full Text] [Related]  

  • 4. Widespread renal polycystosis induced by crizotinib.
    Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
    Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
    Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
    J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.
    Yanagisawa S; Inoue A; Koarai A; Ono M; Tamai T; Ichinose M
    J Thorac Oncol; 2013 Aug; 8(8):e73-4. PubMed ID: 23857405
    [No Abstract]   [Full Text] [Related]  

  • 8. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
    Zhang Y; Yin J; Peng F
    Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
    [No Abstract]   [Full Text] [Related]  

  • 11. Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.
    Pop O; Pirvu A; Toffart AC; Moro-Sibilot D
    J Thorac Oncol; 2012 Aug; 7(8):e1-2. PubMed ID: 22797152
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
    Cao Y; Xiao G; Qiu X; Ye S; Lin T
    PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
    Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
    Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
    Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
    J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
    CsToth I; Meert AP; Sculier JP; Berghmans T
    Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.
    Falk AT; Poudenx M; Otto J; Ghalloussi H; Barrière J
    Lung Cancer; 2012 Dec; 78(3):282-4. PubMed ID: 22999080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Anai S; Takeshita M; Ando N; Ikematsu Y; Mishima S; Ishida K; Inoue K
    J Thorac Oncol; 2016 Oct; 11(10):e126-8. PubMed ID: 27663401
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.